FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912553198> ?p ?o ?g. }

• W2912553198 endingPage "S378" @default.
• W2912553198 startingPage "S377" @default.
• W2912553198 abstract "Vedolizumab is a gut-selective, humanised, monoclonal α4β7 integrin antibody approved for intravenous (IV) administration to treat adult patients with moderate–severe ulcerative colitis (UC). The VISIBLE 1 study assessed the efficacy and safety of a novel vedolizumab formulation for subcutaneous (SC) administration in adult patients with moderate–severe UC. We report the exposure–response and immunogenicity results for vedolizumab SC vs. vedolizumab IV. Pharmacokinetic (PK) and exposure–response data for vedolizumab IV are published.1,2 VISIBLE 1 (NCT02611830) was a Phase 3, double-blind, double-dummy, randomised, placebo-controlled trial. After open-label vedolizumab IV induction treatment (300 mg IV at Weeks [Weeks] 0 and 2), patients with a clinical response at WK6 were randomised to maintenance treatment with placebo, vedolizumab 108 mg every 2 weeks SC, or vedolizumab 300 mg every 8 weeks IV. PK serum samples were taken at prespecified time points. Descriptive statistics were used to summarise vedolizumab PK and immunogenicity using a drug-tolerant electrochemiluminescence assay. Vedolizumab trough concentrations (Ctrough) at WK46 (the final comparable trough sample) were grouped by quartiles and clinical outcome rates were calculated. A total of 216 patients were randomised to placebo (n = 56), vedolizumab SC (n = 106), and vedolizumab IV (n = 54). Both higher vedolizumab SC Ctrough and vedolizumab IV Ctrough concentrations were associated with greater efficacy at WK52, with improved response for low-exposure patients in the SC arm. An increase in WK52 clinical remission was observed in both arms, from 50% to 83% of patients in SC and from 18% to 90% in IV. An increase in WK52 mucosal healing was observed in 50% to 89% of patients in SC and 27% to 100% of patients in IV. A similar trend was observed for both predicted steady-state average concentration and troughs. WK52 exposure–response results for vedolizumab IV were generally comparable with GEMINI 1 results. [1] Immunogenicity was similar for vedolizumab SC and IV and was not associated with injection-site or hypersensitivity reactions. Exposure–response relationships in VISIBLE 1 were similar to those seen previously in GEMINI 1.1,2 Higher serum concentrations of vedolizumab with SC and IV administration during maintenance therapy are associated with greater proportions of patients achieving clinical remission and mucosal healing. Figure 1. Week 52 vedolizumab SC efficacy according to Ctrough quartiles. References 1. Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet 2017;56:1287-1301. 2. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710." @default.
• W2912553198 created "2019-02-21" @default.
• W2912553198 creator A5025810588 @default.
• W2912553198 creator A5032150391 @default.
• W2912553198 creator A5037686948 @default.
• W2912553198 creator A5038304308 @default.
• W2912553198 creator A5041912518 @default.
• W2912553198 creator A5048464948 @default.
• W2912553198 creator A5052278532 @default.
• W2912553198 creator A5055909694 @default.
• W2912553198 creator A5068806006 @default.
• W2912553198 creator A5090282854 @default.
• W2912553198 creator A5090566767 @default.
• W2912553198 date "2019-01-25" @default.
• W2912553198 modified "2023-10-18" @default.
• W2912553198 title "P529 Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1" @default.
• W2912553198 doi "https://doi.org/10.1093/ecco-jcc/jjy222.653" @default.
• W2912553198 hasPublicationYear "2019" @default.
• W2912553198 type Work @default.
• W2912553198 sameAs 2912553198 @default.
• W2912553198 citedByCount "2" @default.
• W2912553198 countsByYear W29125531982021 @default.
• W2912553198 countsByYear W29125531982023 @default.
• W2912553198 crossrefType "journal-article" @default.
• W2912553198 hasAuthorship W2912553198A5025810588 @default.
• W2912553198 hasAuthorship W2912553198A5032150391 @default.
• W2912553198 hasAuthorship W2912553198A5037686948 @default.
• W2912553198 hasAuthorship W2912553198A5038304308 @default.
• W2912553198 hasAuthorship W2912553198A5041912518 @default.
• W2912553198 hasAuthorship W2912553198A5048464948 @default.
• W2912553198 hasAuthorship W2912553198A5052278532 @default.
• W2912553198 hasAuthorship W2912553198A5055909694 @default.
• W2912553198 hasAuthorship W2912553198A5068806006 @default.
• W2912553198 hasAuthorship W2912553198A5090282854 @default.
• W2912553198 hasAuthorship W2912553198A5090566767 @default.
• W2912553198 hasBestOaLocation W29125531981 @default.
• W2912553198 hasConcept C112705442 @default.
• W2912553198 hasConcept C126322002 @default.
• W2912553198 hasConcept C142724271 @default.
• W2912553198 hasConcept C204787440 @default.
• W2912553198 hasConcept C27081682 @default.
• W2912553198 hasConcept C2776207728 @default.
• W2912553198 hasConcept C2779134260 @default.
• W2912553198 hasConcept C2780479503 @default.
• W2912553198 hasConcept C71924100 @default.
• W2912553198 hasConcept C90924648 @default.
• W2912553198 hasConceptScore W2912553198C112705442 @default.
• W2912553198 hasConceptScore W2912553198C126322002 @default.
• W2912553198 hasConceptScore W2912553198C142724271 @default.
• W2912553198 hasConceptScore W2912553198C204787440 @default.
• W2912553198 hasConceptScore W2912553198C27081682 @default.
• W2912553198 hasConceptScore W2912553198C2776207728 @default.
• W2912553198 hasConceptScore W2912553198C2779134260 @default.
• W2912553198 hasConceptScore W2912553198C2780479503 @default.
• W2912553198 hasConceptScore W2912553198C71924100 @default.
• W2912553198 hasConceptScore W2912553198C90924648 @default.
• W2912553198 hasIssue "Supplement_1" @default.
• W2912553198 hasLocation W29125531981 @default.
• W2912553198 hasOpenAccess W2912553198 @default.
• W2912553198 hasPrimaryLocation W29125531981 @default.
• W2912553198 hasRelatedWork W2064867978 @default.
• W2912553198 hasRelatedWork W2169313409 @default.
• W2912553198 hasRelatedWork W2186625387 @default.
• W2912553198 hasRelatedWork W2221971298 @default.
• W2912553198 hasRelatedWork W2341879915 @default.
• W2912553198 hasRelatedWork W2890293380 @default.
• W2912553198 hasRelatedWork W3007087481 @default.
• W2912553198 hasRelatedWork W4239741646 @default.
• W2912553198 hasRelatedWork W4244220285 @default.
• W2912553198 hasRelatedWork W4249500390 @default.
• W2912553198 hasVolume "13" @default.
• W2912553198 isParatext "false" @default.
• W2912553198 isRetracted "false" @default.
• W2912553198 magId "2912553198" @default.
• W2912553198 workType "article" @default.